Drugs / Bemcentinib
Trials 15
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03965494 | Jan 2020 → Oct 2023 | central nervous system neoplasm | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Terminated | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT06469138 | Aug → Sep 2022 | COVID-19, acute myeloid leukemia, glioblastoma, malignant mesothelioma +4 | BerGenBio ASA | Completed | No outcome recorded |
| Phase 1 | NCT02922777 | Nov 2016 → Feb 2023 | non-small cell lung carcinoma | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 1/26 trials | ||||||
| Phase 1/2 | NCT06516887 | Dec 2024 → May 2026 | lung adenocarcinoma | The University of Texas Health Science Center at San Antonio | Terminated | No outcome recorded |
| Phase 1/2 | NCT05469178 | Mar 2023 → Apr 2025 | non-small cell lung carcinoma | BerGenBio ASA | Terminated | No outcome recorded |
| Phase 1/2 | NCT03649321 | Jan 2019 → Jun 2022 | pancreatic adenocarcinoma | University of Texas Southwestern Medical Center | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT02872259 | Feb 2017 → May 2024 | melanoma | Haukeland University Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT02424617 | Apr 2015 → Aug 2021 | non-small cell lung carcinoma | BerGenBio ASA | Completed | No outcome recorded |
| Phase 1/2 | NCT02488408 | Oct 2014 → Jun 2022 | acute myeloid leukemia, myelodysplastic syndrome | BerGenBio ASA | Completed | No outcome recorded |
| Phase 25 trials · 1 met primary | ||||||
| Phase 2 | NCT04890509 | Oct 2020 → May 2021 | COVID-19 | BerGenBio ASA | Completed | No outcome recorded |
| Phase 2 | NCT03654833 | Jan 2019 → Oct 2023 | malignant mesothelioma | University of Leicester | Unknown | Met primary |
| Phase 2 | NCT03824080 | Dec 2018 → Jul 2020 | acute myeloid leukemia, myelodysplastic syndrome | GWT-TUD GmbH | Completed | No outcome recorded |
| Phase 2 | NCT03184571 | Oct 2017 → Oct 2022 | lung adenocarcinoma | BerGenBio ASA | Completed | No outcome recorded |
| Phase 2 | NCT03184558 | Jul 2017 → Aug 2018 | inflammatory breast carcinoma, triple-negative breast carcinoma | BerGenBio ASA | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07445048 | Mar 2026 → Mar 2028 expected | head and neck squamous cell carcinoma | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Recruiting | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bemcentinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03649321 ↗ |
| Known as | BGB324 | “This is an open-label, single-arm multicenter, phase II study. The primary objective is to assess the efficacy of bemcentinib (BGB324) a highly selective inhibitor of the AXL...” NCT03824080 ↗5“Participants received Bemcentinib (BGB324) capsules orally once daily as a loading dose of 400 milligram (mg) on Days 1, 2, and 3.” NCT03184558 ↗ “Participants receive AXL inhibitor BGB324 orally (PO) once daily (QD) on days 1-5” NCT03965494 ↗ |
| Known as | CS-1046 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3809489 ↗ |
| Known as | HY-15150 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3809489 ↗ |
| Known as | KB-80319 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3809489 ↗ |
| Known as | QC-11751 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3809489 ↗ |
| Known as | R428 | “It was shown that a blockade of the Gas6/Axl signaling axis by R428 (bemcentinib) significantly impaired MDS growth in an ex-vivo stroma-dependent co-culture setting using...” NCT03824080 ↗ |
| Known as | SYN-1131 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3809489 ↗ |
| Known as | W-5845 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3809489 ↗ |
| Action | Inhibit | “inhibitor of AXL” NCT02424617 ↗ |
| Modality | Small molecule | “potent selective small molecule inhibitor of AXL” NCT02424617 ↗ |
| Route | Oral | “Bemcentinib was administered orally according to a daily schedule” NCT02488408 ↗ |
| Target | AXL | “inhibitor of AXL” NCT02424617 ↗ |